Home › Funds › Soleus Capital Management, L.P. › TGTX

Soleus Capital Management, L.P. position in TGTX

TG THERAPEUTICS · Health Care

Soleus Capital Management, L.P. reported holding 2,927,895 shares of TGTX (TG THERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$160.9M, representing 5.54% of its reported portfolio and ranking #3 among its reported holdings. Soleus Capital Management, L.P. has disclosed TGTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.93M sh
Reported value held$160.86M
Portfolio Weight5.54%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s TGTX position evolved

Soleus Capital Management, L.P. first disclosed a stake in TGTX in Q3 2023 at 2,884,382 shares (US$24.1M). The position peaked in Q2 2026 at 2,927,895 shares, worth US$160.9M. Across 12 filings, Soleus Capital Management, L.P. increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,927,895 shares valued at US$160.9M — a reduction of -1,101,424 shares quarter over quarter.. Notable position changes include a 77% trim in Q4 2023 (shares fell 11% over the following quarter), a 387% increase in Q1 2024 (shares rose 17% over the following quarter), a 71% increase in Q3 2025 (shares fell 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.88M $24.11M New
Q4 2023 650.00K $11.10M Reduce
Q1 2024 3.17M $48.19M Add
Q2 2024 3.65M $64.85M Add
Q3 2024 2.53M $59.28M Reduce
Q4 2024 2.68M $80.71M Add
Q1 2025 2.85M $112.25M Add
Q2 2025 2.24M $80.76M Reduce
Q3 2025 3.84M $138.89M Add
Q4 2025 3.14M $93.58M Reduce
Q1 2026 4.03M $133.85M Add
Q2 2026 2.93M $160.86M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TGTX and 13F data

TGTX (TG THERAPEUTICS) is a Health Care company. 52 other funds we track also report a position in TGTX — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$145.4M), Penn Capital Management Company, LLC (US$29.5M), Opaleye Management Inc. (US$29.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TGTX

All TGTX fund holders →

FAQ

How long has Soleus Capital Management, L.P. held TGTX?

Soleus Capital Management, L.P. has disclosed TGTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Soleus Capital Management, L.P.'s current position in TGTX?

As of Q2 2026, Soleus Capital Management, L.P. holds 2.93M shares of TGTX (TG THERAPEUTICS), valued at $160.86M, representing 5.54% of its reported portfolio and ranking #3.

Has Soleus Capital Management, L.P. been buying or selling TGTX?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. reduced its position in TGTX. The position peaked in Q2 2026 at 2.93M shares.

Which other funds hold TGTX?

Other major institutional holders of TGTX include CONGRESS ASSET MANAGEMENT CO, Penn Capital Management Company, LLC, Opaleye Management Inc., among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.